New targeted pill for KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new targeted pill (JMKX001899) against a standard chemotherapy drug (docetaxel) for people whose non-small cell lung cancer has a specific gene change called KRAS G12C and has already been treated with chemo and immunotherapy. The goal is to see if the new pill slows the cancer better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with non-small cell lung cancer.
- Your cancer has already been treated with at least one round of chemotherapy that includes platinum and an immunotherapy drug (like Keytruda or Opdivo), and it has spread or come back.
- Your tumor has a certain genetic change called KRAS G12C.
- You have not taken a drug that targets KRAS G12C before, nor have you had docetaxel (Taxotere) for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.